Pfizer, Johnson drop tests for new Alzheimer drug

By Agence France-Presse
Monday, August 6, 2012 21:12 EDT
google plus icon
Pills via AFP
  • Print Friendly and PDF
  • Email this page

NEW YORK — Pfizer and Johnson & Johnson said Monday they had given up tests of a new therapy to treat Alzheimer’s disease, saying the treatment did not measure up to expectations.

The final, phase 3 trial of the intravenous bapineuzumab therapy did not meet targets for effectiveness in aiding cognitive and functional performance of Alzheimer’s victims, according to the two drug giants.

As a result, they decided to end the program to develop the treatment, they said.

“We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer’s disease and their caregivers,” said Steven Romano, senior vice president at Pfizer Inc.

“Yet these data, and the subgroup and biomarker analyses under way, will further inform our understanding of this complex disease and advance research in this field.”

Agence France-Presse
Agence France-Presse
AFP journalists cover wars, conflicts, politics, science, health, the environment, technology, fashion, entertainment, the offbeat, sports and a whole lot more in text, photographs, video, graphics and online.
By commenting, you agree to our terms of service
and to abide by our commenting policy.